Pasithea Therapeutics Corp.: insider trades · United States · SEC (Form 4)

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. is a U.S.-listed biotechnology company quoted on the NASDAQ under the symbols KTTA and KTTAW. Its principal executive offices are in Miami Beach, Florida, United States. The company was incorporated in 2020 and completed its IPO in September 2021. Over time, Pasithea shifted away from an earlier focus on central nervous system and psychiatric/neurological programs toward a more concentrated development strategy centered on precision oncology, RASopathies, and selected rare genetic diseases. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1841330/000121390025110093/ea0264188-10q_pasithea.htm?utm_source=openai)) Pasithea’s lead asset is PAS-004, a next-generation oral macrocyclic MEK inhibitor. The program is being developed primarily for neurofibromatosis type 1 (NF1), especially plexiform neurofibromas, and more broadly for MAPK-pathway-driven tumors and other RAS/MAPK-related indications. The company has also described potential applications in patients with solid tumors carrying documented RAS, NF1 or RAF mutations, and in patients who have failed prior BRAF/MEK inhibition. In practical terms, Pasithea is now a single-asset clinical-stage biotech, so the investment case is driven almost entirely by PAS-004 clinical and regulatory execution. ([ir.pasithea.com](https://ir.pasithea.com/news-events/press-releases/detail/116/pasithea-therapeutics-announces-completion-of-enrollment?utm_source=openai)) From a competitive standpoint, Pasithea operates in a highly crowded and capital-intensive segment of biotechnology. Larger pharma and biotech peers have meaningful advantages in funding, clinical infrastructure, and regulatory experience. Pasithea’s differentiation is based on PAS-004’s macrocyclic chemistry and the company’s effort to build a profile around tolerability, pharmacokinetics, and target engagement. However, the company remains a development-stage micro-cap with no established commercial revenue base, which means the equity story is inherently high risk and highly dependent on future clinical readouts. ([ir.pasithea.com](https://ir.pasithea.com/news-events/press-releases/detail/131/pasithea-therapeutics-announces-positive-pas-004-tablet?utm_source=openai)) Recent milestones have been important for the stock narrative. In 2025, Pasithea reported opening European clinical trial sites, advancing its Phase 1 enrollment, and releasing positive interim pharmacodynamic and pharmacokinetic updates, alongside public financings to support ongoing development. In April 2026, the company announced that the FDA granted Rare Pediatric Disease Designation to PAS-004 for NF1, a potentially meaningful regulatory signal that may enhance the program’s strategic optionality if development continues to progress. For investors, Pasithea should be viewed as a speculative clinical-stage biotech with significant upside potential in the event of positive data, but also with financing dilution and execution risk typical of early-stage drug developers. ([ir.pasithea.com](https://ir.pasithea.com/news-events/press-releases/detail/111/pasithea-therapeutics-announces-opening-of-european?utm_source=openai))